as 11-15-2024 4:00pm EST
Prenetics Global Ltd is a health sciences company, that is dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
Founded: | 2014 | Country: | Hong Kong |
Employees: | N/A | City: | N/A |
Market Cap: | 60.2M | IPO Year: | N/A |
Target Price: | $9.00 | AVG Volume (30 days): | 5.3K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.13 | EPS Growth: | N/A |
52 Week Low/High: | $2.85 - $7.84 | Next Earning Date: | 11-26-2024 |
Revenue: | $22,662,330 | Revenue Growth: | -91.88% |
Revenue Growth (this year): | 64.44% | Revenue Growth (next year): | 154.24% |
PRE Breaking Stock News: Dive into PRE Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
ACCESSWIRE
5 days ago
GlobeNewswire
18 days ago
PR Newswire
a month ago
PR Newswire
a month ago
GlobeNewswire
3 months ago
PR Newswire
4 months ago
GlobeNewswire
5 months ago
The information presented on this page, "PRE Prenetics Global Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.